

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

RIBES, G. et al.

Atty. Ref.: 1721-49

Serial No. unknown

Group:

US National Phase of PCT/FR/02361

Filed: February 27, 2002

Examiner:

For: USE OF AMINO ACIDS FOR MAKING MEDICINES FOR TREATING TO INSULIN-
RESISTANCE

* * * * *

February 27, 2002

Assistant Commissioner for Patents

Washington, DC 20231

Sir:

PRELIMINARY AMENDMENT

Preliminariy amend the above-identified application as follows:

IN THE SPECIFICATION

Amend the specification as follows.

Page 1, before the first line, please insert as a separate paragraph:

--This application is the US national phase of international application PCT/FR00/02361
filed 23 August 2000, which designated the US.--

IN THE CLAIMS

Amend the claims as follows:


RIBES, G. et al.

Serial No. **unknown**

US National Phase of PCT/FR/02361

3) (Amended) Use according to claim 1, characterised in that said compound reduces phosphatase activity associated with the signalling route of the insulin receptor, and/or stimulates PI 3-kinase activity on IRS-1 and/or IRS-2.

4) (Amended) Use according to claim 1, characterised in that said compound is 4-hydroxyisoleucine of formula



and/or the lactonic form of this amino acid.

6) (Amended) Use according to claim 1, for the manufacture of a medicament intended for the treatment of insulin resistance.

7) (Amended) Use according to claim 1, for the manufacture of a medicament intended to combat the syndromes associated with insulin resistance.

8) (Amended) Use according to claim 1, for the manufacture of a medicament against hyperinsulinemia.

9) (Amended) Use according to claim 1, for the manufacture of a medicament against insulin resistance associated with ageing.

10) (Amended) Use of claim 1, for the manufacture of a medicament against illnesses associated with obesity.

RIBES, G. et al.

Serial No. **unknown**

US National Phase of PCT/FR/02361

11) (Amended) Use according to claim 1, for the manufacture of a medicament intended to inhibit the proliferation of cell lines associated with the risk of the appearance of cancer.

12) (Amended) Use according to claim 1, for the manufacture of a medicament intended for the prevention of insulin resistance.

13) (Amended) Use according to claim 1, for the manufacture of a medicament intended to reduce the need for exogenic insulin.


REMARKS

The claims have been amended to reduce multiple dependencies and reduce the filing costs, without prejudice.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By:



B. J. Sadoff
Reg. No. 36,663

BJS:ecb

1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

RIBES, G. et al.

Serial No. **unknown**

US National Phase of PCT/FR/02361

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE SPECIFICATION


Page 1, before the first line, please insert as a separate paragraph:

This application is the US national phase of international application PCT/FR00/02361 filed 23 August 2000, which designated the US.

IN THE CLAIMS

3) (Amended) Use according to claim 1 ~~or~~ 2, characterised in that said compound reduces phosphatase activity associated with the signalling route of the insulin receptor, and/or stimulates PI 3-kinase activity on IRS-1 and/or IRS-2.

4) (Amended) Use according to ~~any one of the previous claims~~ 1, characterised in that said compound is 4-hydroxyisoleucine of formula



and/or the lactonic form of this amino acid.

6) (Amended) Use according to ~~any one of claims 1 to 5~~, for the manufacture of a medicament intended for the treatment of insulin resistance.

7) (Amended) Use according to ~~any one of claims 1 to 6~~, for the manufacture of a medicament intended to combat the syndromes associated with insulin resistance.

8) (Amended) Use according to ~~any one of claims 1 to 7~~, for the manufacture of a medicament against hyperinsulinemia.

RIBES, G. et al.

Serial No. **unknown**

US National Phase of PCT/FR/02361

9) (Amended)Use according to ~~any of claims 1 to 7~~, for the manufacture of a medicament against insulin resistance associated with ageing.

10) (Amended)Use of ~~any one of claims 1 to 7~~, for the manufacture of a medicament against illnesses associated with obesity.

11) (Amended)Use according to ~~any one of claims 1 to 7~~, for the manufacture of a medicament intended to inhibit the proliferation of cell lines associated with the risk of the appearance of cancer.

12) (Amended)Use according to ~~any one of claims 1 to 5~~, for the manufacture of a medicament intended for the prevention of insulin resistance.

13) (Amended)Use according to ~~any one of claims 1-5, and 12~~, for the manufacture of a medicament intended to reduce the need for exogenic insulin.